New biomarkers for drug-induced liver injury: Are they really better? What do they diagnose?

Liver International

Volumn 34, Issue 3, 2014, Pages 325-327

  Senior, John R ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

BLOOD; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; HUMAN; LIVER;

BIOLOGICAL MARKERS; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER;

EID: 84893643513     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12384     Document Type: Editorial

References (14)

1. Thulin P, Nordahl G, Gry M, et al. Keratin-18 and microRNA-122 complement alanine aminotransferase (ALT) as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Intl 2014; 34: 367-78.
2. Paone JF, Waalkes TP, Baker RR, Shaper JH. Serum UDP-galactosyl transferase as a potential biomarker for breast cancer. J Surg Oncol 1980; 15: 59-66.
3. Webb KS, Lin GH. Urinary fibronectin: potential as a biomarker in prostatic cancer. Invest Urol 1980; 17: 401-4.
4. Karmen A, Wroblewski F, Ladue JS. Transaminase activity in human blood. J Clin Invest 1955; 34: 126-33.
5. Wroblewski F, Ladue JS. Serum glutamic oxalacetic transaminase activity as an index of liver cell injury: a preliminary report. Ann Intern Med 1955; 43: 345-60.
6. Winnike JH, Li Z, Wright FA, et al. Use of phamaco-metabonomics for early prediction of acetaminophen-induced hepatotoxicity in humans. Clin Pharmacol Ther 2010; 88: 45-51.
7. Yimer G, Ueda N, Habtewold A, et al. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One 2011; 6: e27810.
8. Rafter I, Gråberg T, Kotronen A, et al. Isoform-specific alanine aminotransferase measurement can distinguish hepatoic from extrahepatic injury in humans. Int J Mol Med 2012; 30: 1241-9.
9. Watkins PB, Desai M, Berkowitz SD, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf 2011; 34: 243-52.
10. Rockey DC, Seeff LB, Rochon J, et al. US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010; 51: 2117-26.
11. Zimmerman HJ. The spectrum of hepatotoxicity. Perspect Biol Med 1968; 12: 135-61.
12. Vecchio TJ. Predictive value of a single diagnostic test in unselected populations. N Eng J Med 1966; 274: 471-3.
13. Antoine DJ, Jenkins RE, Dear JW, et al. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acepatminphen hepatotoxicity. J Hepatol 2012; 58: 1070-9.
14. Adebayo D, Mookerjee RP, Jalan R. Mechanistic biomarkers in acute liver injury: are we there yet? J Hepatol 2012; 56: 1003-5.